Pharmacokinetics and Pharmacdynamics of Sildenafil
- Conditions
- Pulmonary Hypertension
- Interventions
- Procedure: Obtain blood specimens
- Registration Number
- NCT00718185
- Lead Sponsor
- Children's Hospital of Philadelphia
- Brief Summary
The study is being done to investigate what happens to sildenafil in the body and how long it takes to get rid of this drug. Understanding how long the drug stays in the body and how it is changed by the body will help doctors determine the best dose. We also want to learn how well the medicine works based on the size of the dose or amount in the bloodstream.
- Detailed Description
There is no data regarding sildenafil drug disposition in infants and children with pulmonary hypertension. Sildenafil is used at The Children's Hospital of Philadelphia for the treatment of pulmonary hypertension. Patients receiving sildenafil as standard of care will be approached for consent.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 9
- Receive enteral sildenafil as standard of care
- > 28 days to >18 years of age
- Informed consent/assent
- Parents/guardians and/or subjects who, in the opinion of the investigator, may be noncompliant with study schedules or procedures.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description A Obtain blood specimens Patients receiving sildenafil as standard of care
- Primary Outcome Measures
Name Time Method To define the PK of sildenafil administered as standard of care in infants with pulmonary hypertension predose, .5mins after dose, 2-4 hrs after dose, and 5-7 hrs after dose
- Secondary Outcome Measures
Name Time Method To describe the PD effects of sildenafil administered as standard of care in infants and children with pulmonary hypertension. Multiple time points throughout the study
Trial Locations
- Locations (1)
The Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States